Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 803.75 INR -0.06% Market Closed
Market Cap: 350.2B INR
Have any thoughts about
Ajanta Pharma Ltd?
Write Note

Ajanta Pharma Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ajanta Pharma Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Ajanta Pharma Ltd
NSE:AJANTPHARM
Pre-Tax Income
â‚ą11.8B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
â‚ą72.3B
CAGR 3-Years
35%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
â‚ą61.3B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
â‚ą128.4B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
â‚ą25.8B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
9%
M
Mankind Pharma Ltd
NSE:MANKIND
Pre-Tax Income
â‚ą24B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ajanta Pharma Ltd
Glance View

Market Cap
350.2B INR
Industry
Pharmaceuticals

In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.

AJANTPHARM Intrinsic Value
1 935.13 INR
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Ajanta Pharma Ltd's Pre-Tax Income?
Pre-Tax Income
11.8B INR

Based on the financial report for Sep 30, 2024, Ajanta Pharma Ltd's Pre-Tax Income amounts to 11.8B INR.

What is Ajanta Pharma Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
18%

Over the last year, the Pre-Tax Income growth was 37%. The average annual Pre-Tax Income growth rates for Ajanta Pharma Ltd have been 8% over the past three years , 18% over the past five years .

Back to Top